About West Pharmaceutical Services (NYSE:WST)
West Pharmaceutical Services, Inc. is a manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. The Company's products include vial containment solutions, prefillable systems, self-injection platforms, cartridge systems and components, reconstitution and transfer systems, intradermal delivery solutions, specialty components, and contract manufacturing and analytical services. The Company's segments include Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment develops commercial and operational strategies across its global network, with specific emphasis on product offerings to biologic, generic and pharmaceutical drug customers. The Contract-Manufactured Products segment serves as an integrated business focused on the design, manufacture and automated assembly of various devices, primarily for pharmaceutical, diagnostic and medical device customers.
Industry, Sector and Symbol
Industry MED PRODS
Sub-IndustryHealth Care Supplies
Trailing P/E Ratio43.2814070351759
Forward P/E Ratio30.22
Sales & Book Value
Annual Sales$1.60 billion
Price / Sales3.99
Cash Flow$4.01 per share
Price / Cash21.48
Book Value$17.24 per share
Price / Book5.00
Net Income$150.70 million
Return on Equity14.68%
Return on Assets9.97%
West Pharmaceutical Services (NYSE:WST) Frequently Asked Questions
What is West Pharmaceutical Services' stock symbol?
West Pharmaceutical Services trades on the New York Stock Exchange (NYSE) under the ticker symbol "WST."
How often does West Pharmaceutical Services pay dividends? What is the dividend yield for West Pharmaceutical Services?
West Pharmaceutical Services announced a quarterly dividend on Thursday, February 15th. Shareholders of record on Wednesday, April 18th will be given a dividend of $0.14 per share on Wednesday, May 2nd. This represents a $0.56 annualized dividend and a yield of 0.65%. The ex-dividend date is Tuesday, April 17th. View West Pharmaceutical Services' Dividend History.
How will West Pharmaceutical Services' stock buyback program work?
West Pharmaceutical Services declared that its Board of Directors has initiated a share repurchase plan on Thursday, February 15th 2018, which authorizes the company to repurchase 800,000 outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to repurchase shares of its stock through open market purchases. Stock repurchase plans are typically an indication that the company's board of directors believes its stock is undervalued.
How were West Pharmaceutical Services' earnings last quarter?
West Pharmaceutical Services Inc. (NYSE:WST) announced its earnings results on Thursday, February, 15th. The medical instruments supplier reported $0.64 earnings per share for the quarter, beating the consensus estimate of $0.62 by $0.02. The medical instruments supplier had revenue of $415.60 million for the quarter, compared to analysts' expectations of $416.90 million. West Pharmaceutical Services had a return on equity of 14.68% and a net margin of 9.42%. The firm's quarterly revenue was up 8.7% on a year-over-year basis. During the same period last year, the company posted $0.54 earnings per share. View West Pharmaceutical Services' Earnings History.
When will West Pharmaceutical Services make its next earnings announcement?
What guidance has West Pharmaceutical Services issued on next quarter's earnings?
West Pharmaceutical Services issued an update on its FY18 earnings guidance on Thursday, February, 15th. The company provided earnings per share (EPS) guidance of $2.80-2.90 for the period, compared to the Thomson Reuters consensus estimate of $2.90. The company issued revenue guidance of $1.72-1.73 billion, compared to the consensus revenue estimate of $1.73 billion.
Where is West Pharmaceutical Services' stock going? Where will West Pharmaceutical Services' stock price be in 2018?
5 analysts have issued 12-month target prices for West Pharmaceutical Services' stock. Their forecasts range from $98.00 to $115.00. On average, they anticipate West Pharmaceutical Services' share price to reach $106.80 in the next twelve months. View Analyst Ratings for West Pharmaceutical Services.
Are investors shorting West Pharmaceutical Services?
West Pharmaceutical Services saw a increase in short interest during the month of February. As of February 28th, there was short interest totalling 2,006,057 shares, an increase of 56.9% from the February 15th total of 1,278,571 shares. Based on an average daily trading volume, of 545,686 shares, the short-interest ratio is currently 3.7 days. Currently, 2.8% of the shares of the stock are short sold.
Who are some of West Pharmaceutical Services' key competitors?
Some companies that are related to West Pharmaceutical Services include Olympus (OCPNY), ABIOMED (ABMD), DENTSPLY SIRONA (XRAY), Teleflex (TFX), Perrigo (PRGO), Varian Medical Systems (VAR), Cooper Companies (COO), Hologic (HOLX), Sonova (SONVY), William Demant Hol (WILYY), Henry Schein (HSIC), Straumann (SAUHF), Steris (STE), Bio-Rad Laboratories (BIO), DexCom (DXCM), Hill-Rom (HRC), Gn Store Nord (GNNDY) and ICU Medical (ICUI).
Who are West Pharmaceutical Services' key executives?
West Pharmaceutical Services' management team includes the folowing people:
- Eric Mark Green, President, Chief Executive Officer, Director (Age 47)
- William J. Federici, Chief Financial Officer, Senior Vice President, Treasurer (Age 57)
- Annette F. Favorite, Chief Human Resource Officer, Senior Vice President (Age 52)
- George Lloyd Miller J.D., Senior Vice President, General Counsel, Corporate Secretary (Age 62)
- Silji Abraham, Senior Vice President and Chief Digital and Transformation Officer
- Karen A. Flynn, Senior Vice President and Chief Commercial Officer (Age 54)
- David A. Montecalvo, Senior Vice President - Global Operations and Supply Chain (Age 51)
- Eric Resnick, Chief Technology Officer, Vice President (Age 53)
- Daniel Malone, Vice President, Corporate Controller (Age 55)
- Michael A. Anderson, Vice President, Treasurer (Age 61)
Has West Pharmaceutical Services been receiving favorable news coverage?
Headlines about WST stock have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies positive and negative press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. West Pharmaceutical Services earned a daily sentiment score of 0.16 on Accern's scale. They also gave headlines about the medical instruments supplier an impact score of 45.95 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next several days.
Who are West Pharmaceutical Services' major shareholders?
West Pharmaceutical Services' stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (8.39%), Franklin Resources Inc. (5.26%), Alliancebernstein L.P. (2.75%), Bamco Inc. NY (2.42%), William Blair Investment Management LLC (1.71%) and Fisher Asset Management LLC (1.41%). Company insiders that own West Pharmaceutical Services stock include Daniel Malone, Karen Flynn, Patrick J Zenner, Paula A Johnson, Thomas W Hofmann and William J Federici. View Institutional Ownership Trends for West Pharmaceutical Services.
Which major investors are selling West Pharmaceutical Services stock?
WST stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Goldman Sachs Group Inc., Eagle Asset Management Inc., Allianz Asset Management GmbH, American Century Companies Inc., GW&K Investment Management LLC, Two Sigma Advisers LP and Renaissance Technologies LLC. Company insiders that have sold West Pharmaceutical Services company stock in the last year include Daniel Malone and William J Federici. View Insider Buying and Selling for West Pharmaceutical Services.
Which major investors are buying West Pharmaceutical Services stock?
WST stock was purchased by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., TCW Group Inc., Carillon Tower Advisers Inc., William Blair Investment Management LLC, BlackRock Inc., Brown Advisory Inc., Schroder Investment Management Group and McCollum Christoferson Group LLC. View Insider Buying and Selling for West Pharmaceutical Services.
How do I buy shares of West Pharmaceutical Services?
Shares of WST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is West Pharmaceutical Services' stock price today?
One share of WST stock can currently be purchased for approximately $86.13.
How big of a company is West Pharmaceutical Services?
West Pharmaceutical Services has a market capitalization of $6.58 billion and generates $1.60 billion in revenue each year. The medical instruments supplier earns $150.70 million in net income (profit) each year or $1.99 on an earnings per share basis. West Pharmaceutical Services employs 7,500 workers across the globe.
How can I contact West Pharmaceutical Services?
West Pharmaceutical Services' mailing address is 530 HERMAN O. WEST DRIVE, EXTON PA, 19341. The medical instruments supplier can be reached via phone at 610-594-2900 or via email at [email protected]
MarketBeat Community Rating for West Pharmaceutical Services (WST)MarketBeat's community ratings are surveys of what our community members think about West Pharmaceutical Services and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
West Pharmaceutical Services (NYSE:WST) Analysts' Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Hold||Hold||Buy||Buy|
|Consensus Rating Score: ||2.40||2.40||2.50||3.00|
|Ratings Breakdown: ||0 Sell Rating(s)|
3 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
3 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
|Consensus Price Target: ||$106.80||$106.80||$106.00||$93.78|
|Price Target Upside: ||24.00% upside||6.40% upside||5.02% upside||2.24% upside|
West Pharmaceutical Services (NYSE:WST) Consensus Price Target History
West Pharmaceutical Services (NYSE:WST) Analyst Ratings History
(Data available from 3/24/2016 forward)
West Pharmaceutical Services (NYSE:WST) Earnings History and Estimates Chart
West Pharmaceutical Services (NYSE WST) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|2/15/2018||Q4 2017||$0.62||$0.64||$416.90 million||$415.60 million||View||N/A|
|10/26/2017||Q3 2017||$0.53||$0.67||$386.02 million||$398.20 million||View||N/A|
|7/27/2017||Q2 2017||$0.65||$0.66||$406.00 million||$397.60 million||View||N/A|
|4/27/2017||Q1 2017||$0.55||$0.81||$380.42 million||$387.70 million||View||N/A|
|2/16/2017||Q416||$0.56||$0.54||$387.31 million||$382.30 million||View||Listen|
|10/27/2016||Q316||$0.53||$0.53||$371.76 million||$376.70 million||View||Listen|
|7/28/2016||Q216||$0.56||$0.59||$384.58 million||$388.00 million||View||Listen|
|4/28/2016||Q116||$0.51||$0.53||$355.86 million||$362.10 million||View||Listen|
|2/18/2016||Q415||$0.47||$0.47||$364.76 million||$359.70 million||View||Listen|
|10/29/2015||Q315||$0.43||$0.44||$355.90 million||$344.50 million||View||Listen|
|7/30/2015||Q215||$0.45||$0.47||$356.33 million||$359.70 million||View||Listen|
|4/30/2015||Q115||$0.40||$0.45||$346.64 million||$335.90 million||View||Listen|
|2/19/2015||Q414||$0.46||$0.45||$348.33 million||$349.80 million||View||Listen|
|10/30/2014||Q314||$0.43||$0.44||$356.08 million||$355.90 million||View||Listen|
|7/31/2014||Q214||$0.47||$0.52||$368.60 million||$368.90 million||View||N/A|
|5/1/2014||Q114||$0.41||$0.38||$340.90 million||$346.80 million||View||Listen|
|2/20/2014||Q413||$0.38||$0.38||$348.70 million||$342.70 million||View||Listen|
|10/31/2013||Q3 13||$0.36||$0.39||$333.25 million||$341.80 million||View||Listen|
|8/1/2013||Q2 2013||$0.82||$0.86||$349.85 million||$344.50 million||View||Listen|
|5/2/2013||Q1 2013||$0.86||$0.87||$344.20 million||$339.40 million||View||Listen|
|2/21/2013||Q4 2012||$0.56||$0.61||$318.75 million||$321.50 million||View||Listen|
|11/1/2012||Q312||$0.50||$0.52||$306.91 million||$303.80 million||View||N/A|
West Pharmaceutical Services (NYSE:WST) Earnings Estimates
2018 EPS Consensus Estimate: $2.84
(Earnings estimates data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
West Pharmaceutical Services (NYSE:WST) Dividend Information
|Dividend Growth:||8.90% (3 Year Average)|
|Payout Ratio:||28.14% (Trailing 12 Months of Earnings) |
19.65% (Based on This Year's Estimates)
17.34% (Based on Next Year's Estimates)
|Track Record:||25 Years of Consecutive Dividend Growth|
West Pharmaceutical Services (NYSE:WST) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
West Pharmaceutical Services (NYSE WST) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 1.90%
Institutional Ownership Percentage: 94.37%
West Pharmaceutical Services (NYSE WST) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|12/8/2017||William J Federici||CFO||Sell||21,000||$99.01||$2,079,210.00||190,493|| |
|5/18/2017||William J. Federici||CFO||Sell||54,996||$95.45||$5,249,368.20|| |
|5/2/2017||Daniel Malone||VP||Sell||4,124||$93.31||$384,810.44|| |
|12/8/2016||Patrick J. Zenner||Director||Buy||332||$84.53||$28,063.96|| |
|10/31/2016||Paula A. Johnson||Director||Sell||2,466||$75.87||$187,095.42|| |
|9/6/2016||Karen Flynn||SVP||Sell||14,581||$83.28||$1,214,305.68||13,513|| |
|8/23/2016||Paula A Johnson||Director||Sell||3,042||$81.55||$248,075.10||38,450|| |
|6/2/2016||Daniel Malone||VP||Sell||3,950||$74.95||$296,052.50||30,666|| |
|5/25/2016||Thomas W Hofmann||Director||Sell||2,466||$73.57||$181,423.62||34,506|| |
|3/1/2016||Michael A Anderson||VP||Sell||16,414||$63.58||$1,043,602.12||70,507|| |
|2/29/2016||Thomas W Hofmann||Director||Sell||3,042||$62.70||$190,733.40||34,637|| |
|2/25/2016||Heino Lennartz||Insider||Sell||5,680||$62.47||$354,829.60||18,304|| |
|2/24/2016||Heino Lennartz||Insider||Sell||19,658||$59.45||$1,168,668.10||20,911|| |
|2/23/2016||Paula A. Johnson||Director||Sell||7,800||$59.39||$463,242.00|| |
|2/22/2016||Warwick Bedwell||Insider||Sell||16,042||$59.52||$954,819.84||43,623|| |
|11/25/2015||John E. Paproski||insider||Sell||17,560||$63.41||$1,113,479.60||70,288|| |
|11/12/2015||Heino Lennartz||Insider||Sell||3,500||$61.87||$216,545.00||15,435|| |
|11/6/2015||Michael A Anderson||VP||Sell||3,000||$62.18||$186,540.00||61,497|| |
|11/5/2015||Michael A. Anderson||VP||Sell||10,000||$61.98||$619,800.00||64,497|| |
|11/4/2015||Daniel Malone||VP||Sell||4,456||$61.65||$274,712.40||22,627|| |
|8/17/2015||William J Federici||CFO||Sell||52,678||$59.72||$3,145,930.16|| |
|5/28/2015||Heino Lennartz||Insider||Sell||9,584||$55.00||$527,120.00|| |
|5/22/2015||Karen Flynn||Insider||Sell||3,091||$55.24||$170,746.84|| |
|5/21/2015||Eric Mark Green||CEO||Buy||18,300||$54.89||$1,004,487.00|| |
|5/18/2015||Karen Flynn||Insider||Sell||1,909||$55.00||$104,995.00|| |
|5/15/2015||Donald E Morel Jr||CEO||Sell||20,000||$54.29||$1,085,800.00|| |
|2/27/2015||Richard D Luzzi||VP||Sell||10,000||$54.85||$548,500.00|| |
|2/26/2015||Michael A Anderson||VP||Sell||4,682||$54.93||$257,182.26|| |
|2/25/2015||Heino Lennartz||Insider||Sell||3,617||$54.82||$198,283.94|| |
|2/24/2015||John E Paproski||Insider||Sell||9,282||$52.87||$490,739.34|| |
|2/23/2015||Heino Lennartz||Insider||Sell||21,040||$53.40||$1,123,536.00|| |
|2/23/2015||Patrick J Zenner||Director||Sell||12,800||$53.69||$687,232.00|| |
|11/26/2014||Richard D Luzzi||VP||Sell||8,000||$52.11||$416,880.00|| |
|11/21/2014||William J Federici||CFO||Sell||3,000||$51.22||$153,660.00|| |
|11/20/2014||Donald E Morel Jr||CEO||Sell||20,000||$51.30||$1,026,000.00|| |
|11/13/2014||John R Gailey||VP||Sell||28,000||$52.37||$1,466,360.00|| |
|11/11/2014||Michael A Anderson||VP||Sell||4,600||$51.73||$237,958.00|| |
|11/10/2014||Warwick Bedwell||Insider||Sell||6,306||$49.95||$314,984.70|| |
|8/21/2014||Richard D Luzzi||VP||Sell||10,000||$44.07||$440,700.00|| |
|8/20/2014||John R Gailey||VP||Sell||20,000||$43.96||$879,200.00|| |
|8/19/2014||Michael A Anderson||VP||Sell||9,800||$43.41||$425,418.00|| |
|8/18/2014||William J Federici||CFO||Sell||38,366||$42.56||$1,632,856.96|| |
|8/13/2014||Heino Lennartz||Insider||Sell||7,555||$39.65||$299,555.75|| |
|8/11/2014||Heino Lennartz||Insider||Sell||11,445||$40.00||$457,800.00|| |
|8/7/2014||John E Paproski||Insider||Sell||14,000||$40.44||$566,160.00|| |
|5/30/2014||Richard D Luzzi||VP||Sell||22,828||$42.17||$962,656.76|| |
|5/29/2014||Heino Lennartz||Insider||Sell||2,000||$43.00||$86,000.00|| |
|2/28/2014||Heino Lennartz||Insider||Sell||16,044||$45.84||$735,456.96|| |
|2/26/2014||Patrick J Zenner||Director||Sell||12,800||$46.12||$590,336.00|| |
|2/24/2014||Warwick Bedwell||Insider||Sell||24,606||$47.49||$1,168,538.94|| |
|11/26/2013||Donald E Morel Jr||CEO||Sell||35,000||$48.60||$1,701,000.00|| |
|11/22/2013||William J Federici||CFO||Sell||36,000||$48.34||$1,740,240.00|| |
|11/19/2013||Karen Flynn||Insider||Sell||5,500||$47.75||$262,625.00|| |
|11/8/2013||Michael A Anderson||VP||Sell||9,200||$46.80||$430,560.00|| |
|11/7/2013||Heino Lennartz||Insider||Sell||5,102||$46.70||$238,263.40|| |
|11/6/2013||Michael A Anderson||VP||Sell||6,000||$46.53||$279,180.00|| |
|11/5/2013||John R Gailey||VP||Sell||6,000||$46.83||$280,980.00|| |
|11/5/2013||Warwick Bedwell||Insider||Sell||6,304||$46.84||$295,279.36|| |
|11/4/2013||Richard D Luzzi||VP||Sell||38,708||$46.99||$1,818,888.92|| |
|8/30/2013||Donald E Morel Jr||CEO||Sell||10,000||$74.46||$744,600.00|| |
|8/27/2013||John R Gailey||VP||Sell||13,749||$76.77||$1,055,510.73|| |
|8/22/2013||L Robert Johnson||Director||Sell||1,883||$76.81||$144,633.23|| |
|8/14/2013||John E Paproski||Insider||Sell||6,011||$79.08||$475,349.88|| |
|8/12/2013||Anthony Welters||Director||Sell||19,200||$78.43||$1,505,856.00|| |
|8/8/2013||Michael A Anderson||VP||Sell||4,300||$78.00||$335,400.00|| |
|5/31/2013||Michael A Anderson||VP||Sell||4,000||$68.94||$275,760.00|| |
|5/28/2013||Donald E Morel Jr||CEO||Sell||10,000||$67.87||$678,700.00|| |
|5/24/2013||L Robert Johnson||Director||Sell||1,700||$67.47||$114,699.00|| |
|5/20/2013||John R Gailey||VP||Sell||9,282||$68.54||$636,188.28|| |
|5/17/2013||L Robert Johnson||Director||Sell||4,000||$67.80||$271,200.00|| |
|5/8/2013||L Robert Johnson||Director||Sell||6,400||$64.49||$412,736.00|| |
West Pharmaceutical Services (NYSE WST) News Headlines
West Pharmaceutical Services (NYSE:WST) SEC Filings
This page is loading this company's SEC Filings. Please wait...
West Pharmaceutical Services (NYSE:WST) Income Statement, Balance Sheet and Cash Flow Statement
West Pharmaceutical Services (NYSE WST) Stock Chart for Saturday, March, 24, 2018